Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with the Thrombostat 4000

R S Alshameeri1, E F Mammen

  • 1Wayne State University School of Medicine, Detroit, MI, USA.

Seminars in Thrombosis and Hemostasis
|January 1, 1995
PubMed
Summary

The Thrombostat 4000 device shows promise for screening primary hemostasis defects, detecting more patients than traditional bleeding times. However, collagen inconsistencies limit its routine diagnostic use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disseminated intravascular coagulation (DIC).

Clinical laboratory science : journal of the American Society for Medical Technology·2001
Same author

Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease.

Hematology/oncology clinics of North America·2000
Same author

Low molecular weight heparins and heparin-induced thrombocytopenia.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2000
Same author

The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors.

American journal of obstetrics and gynecology·1999
Same author

Sticky platelet syndrome.

Seminars in thrombosis and hemostasis·1999
Same author

Clinical differentiation of low molecular weight heparins.

Seminars in thrombosis and hemostasis·1999

Area of Science:

  • Hematology
  • Clinical Diagnostics

Background:

  • Bleeding times are standard for screening primary hemostasis defects but lack accuracy and reliability.
  • Platelet aggregation studies are unsuitable for routine clinical use.

Purpose of the Study:

  • To evaluate the performance characteristics of the Thrombostat 4000 device for assessing primary hemostasis.
  • To compare the efficacy of the Thrombostat 4000 with traditional bleeding time tests and platelet aggregation studies.

Main Methods:

  • The Thrombostat 4000 assesses primary hemostasis by measuring platelet adhesion to collagen with added agonists (ADP, epinephrine, CaCl2, NaCl).
  • Performance was evaluated in normal volunteers and patients, assessing reference ranges, coefficients of variance, and stability of samples.
  • The device's ability to detect effects of aspirin and primary hemostasis defects was compared to bleeding times.

Main Results:

  • ADP and epinephrine demonstrated acceptable reference ranges (9-12% CV) for within-run and between-run variability.
  • Significant variability was observed due to differences in collagen coatings on filter badges.
  • The Thrombostat 4000 detected more patients with primary hemostasis defects than bleeding times; epinephrine detected aspirin effects, unlike ADP.
  • Epinephrine showed potential for detecting a broad spectrum of platelet defects, including aspirin use and platelet dysfunction.

Conclusions:

  • The Thrombostat 4000 shows potential for improved detection of primary hemostasis defects compared to bleeding times.
  • Inconsistent collagen quality across filter badges presents a significant limitation for the device's routine clinical application.
  • Further standardization of collagen coatings is necessary for reliable routine screening of hemostasis disorders.

Related Experiment Videos